The IMPACT study is an international targeted prostate screening study of men at increased prostate cancer risk due to the presence of known pathogenic mutations in BRCA1 and BRCA2 genes and Mis-Match Repair genes (MLH1, MSH6, MSH2). There are only approximately 150 men with a known BRCA1 or BRCA2 mutation in the UK. Research has shown that these men are at an increased risk of developing prostate cancer but more information is needed about the pathogenesis of prostate cancer in this defined group and the role of screening in these men. The study will offer annual PSA screening to these men to determine the incidence of prostate cancer in this group. The study will also look at new markers of early prostate cancer in this cohort. The power calculations for this study are 850 carriers and 850 controls (age-matched men without BRCA1/2. Mis match repair mutations). It is therefore essential to gain international collaboration to meet the target of recruiting 850 men with these known mutations and a control group of 850 men who have tested negative for a known familial mutation.
Prostate cancer is a significant public health problem. In the EU approximately 200,000 men are diagnosed annually with prostate cancer. There are 24,000 cases per year in England and Wales and 10,000 deaths. The incidence is increasing, even when screen-detected cancers are considered, and within the next few years it will become the most common cancer in UK men. that an alteration in the breast cancer predisposition genes BRCA1 and BRCA2, may predispose to prostate cancer (PC) and this study will increase this evidence-base. There is some evidence, at least in BRCA2 carriers, that the prostate cancer in these men may be more aggressive and so earlier detection could theoretically reduce mortality. It has been reported that unaffected individuals from families with multiple cases of PC show an increased percentage of raised PSA levels, but the use of PSA level and its predictive value in healthy males with BRCA1/2 mutations has not been studied. If PSA were to be used as a screening tool in BRCA1/2 mutation carriers, we would need to gain a better understanding of the pathogenesis of PC in these men and determine whether they have a different baseline PSA profile compared with controls. The high prevalence of hormone-dependent/secreting tumours such as breast, ovary and prostate in BRCA1/2 carriers suggests an important role of hormones and their receptors in the development of cancer. Androgens and androgen receptors are considered crucial elements in PC pathogenesis. Therefore male sex hormones will be measured to determine the hormone profile in BRCA1/2 carriers compared with a control group. There is strong evidence that BRCA1/2 play an important role in DNA repair and cell cycling. Therefore, we will investigate abnormalities of the metabolic processes in individuals with a BRCA1/2 mutation where cell cycling may be abnormal. Analysis of proteins (proteomics) and metabolites (metabonomics) are powerful approaches to identifying proteins and metabolites involved in cancer formation. The analysis of the proteins and metabolites will enable us to investigate the effect of the presence of a BRCA1/2 mutation and aid in the identification of new biomarkers for prostate cancer. The target population is a group of 850 males who carry a known pathogenic mutation in the BRCA1/2 genes (500 BRCA1 and 350 BRCA2). These men will be recruited through genetics clinics across the UK and the world. A control group of men who have tested negative for a known pathogenic mutation that is running in their family will also be recruited through the genetics clinics. All participants will be invited to attend annually for 5 years for an appointment lasting approximately 30 minutes during which they will discuss the study in detail before giving their written consent agreeing to participate. They will have a 50ml blood sample taken and be asked to provide a urine sample every year. They will also be required to complete a short family and medical history questionnaire. These appointments will either take place at the centre they are registered at, at the Royal Marsden Hospital, or in their own home depending on the arrangements made with the collaborating consultant and patient preference. The PSA level of all participants will be measured locally. If PSA is \>3.0ng/ml, a ten core prostatic biopsy will be offered, carried out by a consultant urologist. Ten biopsies will be used for diagnostic purposes, with two extra biopsy samples taken for research analysis with the patients fully informed written consent prior to the procedure being carried out. If any of the ten cores identify the presence of prostate cancer, they will receive treatment for this as advised by their local centre. The PSA will be quality controlled by batch testing at a reference lab. If the value locally was \<3.0ng/ml but is \>3ng/ml in the reference lab it will be remeasured locally. If high grade Prostatic Intraepithelial Neoplasia (PIN) is detected or if the sample is inconclusive then a sextant biopsy repeated after 6 weeks will be recommended, in accordance with the ERSPC protocol. If atypical acini are detected then immediate biopsy will be undertaken.
Study Type
OBSERVATIONAL
Enrollment
3,500
Patients tested for their level of Prostate Specific Antigen.
A Prostate biopsy is given as an option to the patient if their PSA level is raised or at the end of 5 years screening.
Cancer Genetics Unit, Royal Marsden Hospital
Sutton, Surrey, United Kingdom
Primary Endpoint (BRCA)
To determine the yearly incidence of screen-detected prostate cancer in BRCA1 and BRCA2 mutation carriers compared with the control population (predictive test negative for a known familial BRCA1/2 gene mutation). "
Time frame: Through study completion, a minimum of 10 years follow up in participants.
Primary Endpoint (Mismatch Repair/Lynch Cohort)
To determine the yearly incidence of screen-detected prostate cancer in mismatch repair gene mutation carriers compared with the control population (predictive test negative for a known familial MMR gene mutation).
Time frame: Through study completion, a minimum of 10 years follow up in participants.
PSA threshold for prostate cancer detection
To determine age-specific PSA levels (ug/L) for cancer detection in mutation carriers versus controls from: i) a group of men who are age matched (+/- 5 years) and who have a negative predictive genetic test ii) two population based screening studies
Time frame: Through study completion, a minimum of 10 years follow up in participants.
Positive Predictive value of PSA level for prostate cancer detection
To determine the positive predictive value of PSA using a threshold of 3.0ug/L for the development of prostate cancer in mutation carriers using 5 or more years' annual follow up compared with the control populations
Time frame: Through study completion, a minimum of 10 years follow up in participants.
Cancer Pathology (BRCA)
To determine the stage and pathology at cancer diagnosis of screen-detected prostate cancer in BRCA1 and BRCA2 mutation carriers compared with the control population (predictive test negative for a known familial BRCA1/2 gene mutation).
Time frame: Through study completion, a minimum of 10 years follow up in participants.
Cancer Pathology (Mismatch Repair/Lynch Cohort)
To determine the stage and pathology at cancer diagnosis of screen-detected prostate cancer in mismatch repair gene mutation carriers compared with the control population (predictive test negative for a known familial MMR gene mutation).
Time frame: Through study completion, a minimum of 10 years follow up in participants.
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.